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Introduction
IL-18 is a member of the IL-1 cytokine family that was
originally identified as IFN-γ–inducing factor (1). Sim-
ilar to IL-12, IL-18 stimulates Th1 cell differentiation (2,
3), promotes IFN-γ, TNF-α, IL-1β, IL-8, and GM-CSF
secretion (4–6), and enhances natural killer cell cyto-
toxicity (7, 8). The precursor to IL-18, pro–IL-18, is
cleaved by IL-1β–converting enzyme (also known as cas-
pase-1), resulting in the active 18-kDa mature protein
(9). Pro–IL-18 expression has been detected in antigen-
presenting cells such as activated macrophages, Kupffer
cells (7), dendritic cells (10), and Langerhans cells (11),
as well as articular chondrocytes (12) and osteoblasts
(13). The receptor complex for IL-18, IL-18R, is com-
prised of an α chain and a nonbinding β chain, both
members of the IL-1R family. This receptor complex sig-
nals through a pathway that involves myeloid differen-
tiation factor 88, IL-1 receptor-associated kinase, TNF
receptor–associated factor 6 (TRAF6), and NF-κB (14).
Recent studies have elucidated a broad spectrum of
effector functions beyond lymphocyte activation that
implicate IL-18 as an important regulator of chronic
inflammation in human autoimmune diseases (15). It
has recently been reported that elevated levels of IL-18
were observed in synovial fluid from patients with
rheumatoid arthritis (16). IL-18 induces TNF-α, 
GM-CSF, IFN-γ, and nitric oxide production by synovial
cells isolated from patients with rheumatoid arthritis
through a direct, IFN-γ–independent pathway, via con-
stitutive IL-18Rα expression (16). The IL-18–induced
cytokine production by synovial macrophages was
potentiated by IL-12 and/or IL-15, and was suppressed
by IL-10 and TGF-β. Moreover, IL-1β induces mature
IL-18 expression in human articular chondrocytes
through a caspase-1–dependent pathway (12). IL-18
induces chondrocyte proliferation, upregulates
inducible nitric oxide synthase, stromelysin, and
cyclooxygenase-2 expression, and increases gly-
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Two distinct IL-18 neutralizing strategies, i.e. a rabbit polyclonal anti-mouse IL-18 IgG and a recom-
binant human IL-18 binding protein (rhIL-18BP), were used to treat collagen-induced–arthritic
DBA/1 mice after clinical onset of disease. The therapeutic efficacy of neutralizing endogenous 
IL-18 was assessed using different pathological parameters of disease progression. The clinical sever-
ity in mice undergoing collagen-induced arthritis was significantly reduced after treatment with
both IL-18 neutralizing agents compared to placebo treated mice. Attenuation of the disease was
associated with reduced cartilage erosion evident on histology. The decreased cartilage degradation
was further documented by a significant reduction in the levels of circulating cartilage oligomeric
matrix protein (an indicator of cartilage turnover). Both strategies efficiently slowed disease pro-
gression, but only anti–IL-18 IgG treatment significantly decreased an established synovitis. Serum
levels of IL-6 were significantly reduced with both neutralizing strategies. In vitro, neutralizing 
IL-18 resulted in a significant inhibition of TNF-α, IL-6, and IFN-γ secretion by macrophages. These
results demonstrate that neutralizing endogenous IL-18 is therapeutically efficacious in the murine
model of collagen-induced arthritis. IL-18 neutralizing antibody or rhIL-18BP could therefore rep-
resent new disease-modifying anti-rheumatic drugs that warrant testing in clinical trials in patients
with rheumatoid arthritis.
J. Clin. Invest. 108:1825–1832 (2001). DOI:10.1172/JCI200112097.
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cosaminoglycan release (17). More recently, neutraliza-
tion of endogenous IL-18 during the onset of disease in
an acute streptococcal wall–induced joint inflammation
significantly reduced local TNF-α and IL-1β levels (18).
These data indicate that IL-18 could modulate synovial
inflammation during rheumatoid arthritis, and could
therefore represent a novel therapeutic target.
IL-18 binding protein (IL-18BP), a constitutively
expressed and secreted protein, has been identified (19,
20). IL-18BP binds IL-18 with high affinity (400 pM), and
blocks its biological activity at a 1:1 molar ratio (21). Such
a naturally occurring molecule represents an interesting
inhibitor for testing in experimental models of disease.
Administration of collagen type II and CFA in DBA/1
mice is a well-established animal model of rheumatoid
arthritis. In this model, immunization with type II col-
lagen induces the development of an erosive, inflam-
matory arthritis (22), and represents an ideal opportu-
nity to explore the therapeutic potential of novel
molecules (23–25). To this end, endogenous IL-18 was
neutralized in mice with collagen-induced arthritis
(CIA) using either IL-18 neutralizing antibody or
recombinant human IL-18BP (rhIL-18BP), and the
effects of these treatments were evaluated by different
parameters of pathogenicity.
Methods
Induction of CIA. CIA was induced in 8- to 12-week-old
male DBA/1 mice obtained from Bomholdgard Breed-
ing and Research Centre Ltd. (Ry, Denmark) for the
anti–IL-18 treatment, and from Charles River Japan
Inc. (Shin-Yokohama, Japan) for treatment with 
rhIL-18BP. All mice were immunized with native type
II bovine collagen (CII) in emulsified CFA as previous-
ly described (24). Mice used in the anti–IL-18 antibody
experiments received an additional intraperitoneal
immunization with 100 µg of CII in saline at day 21
(26). Starting on day 25 after immunization, mice were
examined daily for onset of disease, which occurs
between days 25 and 30.
Treatment with rabbit anti–IL-18 IgG and rhIL-18BP. Ther-
apeutic treatment of CII-immunized DBA/1 mice was
started at the first appearance of clinical signs of disease
(between days 21 and 30). Two strategies were used to
neutralize endogenous IL-18. The first was a single
intraperitoneal injection (2 mg per mouse) of neutraliz-
ing rabbit anti–IL-18 IgG, prepared by HiTrap Protein G
HP (Amersham Pharmacia Biotech AB, Uppsala, Swe-
den). This dose was shown to be effective in the murine
models of LPS-mediated lethal shock (27) and strepto-
coccal cell wall–induced arthritis (18). Control mice
received normal rabbit IgG. The second neutralizing
agent used was rhIL-18BP isoform a, which was labeled
at the N-terminal with six histamines (rhIL-18BPa-6his).
This was expressed in Chinese hamster ovary cells and
purified to homogeneity (21), then injected intraperi-
toneally daily for 7 days at four different concentrations:
0.25, 0.5, 1, and 3 mg/kg; in this protocol, the control
mice received vehicle only (0.9 % NaCl).
Clinical evaluation of disease progression. From the first
appearance of clinical signs of disease, mice were exam-
ined by an investigator blinded to the treatment. Each
limb was graded for disease severity (clinical scores,
0–3.5; maximum score, 14/mouse). The progression of
swelling (inflammation) was measured on the paw that
first showed signs of disease, using precision calipers
(Brutsch Ruegger AG, Zurich, Switzerland). Disease
progression was monitored daily for 8 days in 
rhIL-18BP–treated mice, and every other day for 15
days in mice treated with anti–IL-18 IgG.
Histological assessment of cartilage erosions and synovial
inflammation. At the termination of the experiments,
mice were sacrificed, and the paws were prepared for
histological analysis. Joints were fixed, decalcified, and
embedded in paraffin. Cryosections (5–7 µm) were
stained with hematoxylin/eosin and safranin O. Each
joint was scored separately by two individuals who were
unaware of the treatment protocol, using the following
erosion scoring scale: no destruction of cartilage or
bone = 0; localized cartilage erosions = 1–2; more
extended erosions = 3; general cartilage destruction and
presence of bone erosions = 4. The final score of each
mouse was the mean of all joints scored. Synovial
inflammation (infiltration and hyperplasia) was scored
from 0 to 4, as follows: no inflammation = 0; slight
thickening of lining layer and/or some infiltrating cells
in the sublining layer = 1–2; thickening of lining layer
and/or a more pronounced influx of cells in the sub-
lining layer = 3; presence of cells in the synovial space,
thickening of lining layer, and synovium highly infil-
trated with numerous inflammatory cells = 4.
Murine IL-18BP and rhIL-18BP quantification. To measure
plasma levels of endogenous murine IL-18BP 
(mIL-18BP), 96-well plates (Combiplate 12 EB; Biocon-
cept, Allschwil, Switzerland) were coated with 0.5 µg/ml
of an affinity purified rabbit polyclonal antibody to
recombinant murine IL-18BPd isoform d, (rmIL-18BPd).
Plasma mIL-18BP was detected using a biotinylated rab-
bit polyclonal antibody raised against E. coli rmIL-18BP
(PeproTech Inc., Rocky Hill, New Jersey, USA), followed
by extravidin-peroxidase conjugate diluted 1:10,000
(Sigma Chemical Co., St. Louis, Missouri, USA). 
rmIL-18BPd produced by HEK 293 cells was used as a
standard. The sensitivity of the ELISA used was 5 ng/ml.
To measure plasma levels of rhIL-18BP, 96-well plates
(Combiplate 12 EB; Bioconcept) were coated with 0.2
µg/ml of an affinity purified rabbit polyclonal antibody
to rhIL-18BPa. Circulating rhIL-18BPa was then detect-
ed using 500 ng/ml of anti–rhIL-18BPa biotinylated
monoclonal antibody (clone 657.27), followed by extra-
vidin-peroxidase conjugate diluted 1:10,000 (Sigma
Chemical Co.). rhIL-18BPa-6his was used as a standard.
The sensitivity of the ELISA used was 50 pg/ml.
Cartilage oligomeric matrix protein measurements. At the
termination of the experiments, serum samples were
collected, and an ELISA to determine cartilage
oligomeric matrix protein (COMP) levels was per-
formed as previously described (28).
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Cytokine assays. Levels of immunoreactive mIL-6
(R&D Systems Inc., Oxon, United Kingdom) and mIL-
18 (Medical and Biological Laboratories Co., Nagoya,
Japan) were determined using ELISA. The detection
limit for mIL-6 was 15 pg/ml; that for mIL-18 was 25
pg/ml. mIL-6 bioactivity was determined by a prolifer-
ative assay using B9 cells. The detection limit for the
mIL-6 bioassay was 1 pg/ml.
Peritoneal macrophage culture. Peritoneal macrophages
from DBA/1 mice were enriched by adherence. Enriched
macrophages (97%) were cultured in supplemented
RPMI 1640 medium at 2 × 106 cells/ml in flat 96-well
plates (Nalge Nunc International, Roskilde, Denmark)
in the presence of mIL-12 (100 ng/ml), mIL-18 (200
ng/ml; R&D Systems Inc.), and rhIL-18BP (1 µg/ml) for
24 hours. The supernatants were assayed for cytokines
by ELISA according to the manufacturer’s instructions
(R&D Systems Inc.). Detection limits were: mIFN-γ, 31
pg/ml, mIL-6 and mTNF-α, 15 pg/ml.
Expression of results. Results are expressed as difference
from the first day of treatment and as area under the
curve. The area under the curve is a cumulative meas-
ure of the effect during the entire experiment, deter-
mined using the formula dx(y1 + y2)/2.
Statistical analysis. Significance of differences was
assessed by the Mann-Whitney U test using the Sigma-
Stat statistical analysis program (SPSS Inc., Chicago,
Illinois, USA) and the GraphPad Prism
program (GraphPad Software Inc., San
Diego, California, USA).
Results
IL-18 levels are increased in the sera of mice with
CIA. On days 4 and 8 after the onset of CIA,
circulating levels of IL-18 were significant-
ly elevated (320 ± 56 pg/ml and 171 ± 62
pg/ml, respectively) compared with the lev-
els measured in naive mice of the same
strain (58 ± 34 pg/ml, P = 0.0012, n = 6 in
each group). This observation demon-
strates induction of endogenous IL-18 dur-
ing the clinical expression of CIA. Endoge-
nous levels of mIL-18BP were below 5
ng/ml, the detection limit of the ELISA.
Neutralization of endogenous IL-18 decreases
the severity of CIA. In order to investigate
whether blocking endogenous IL-18 could
represent a new therapy for rheumatoid
arthritis, two different IL-18 neutralizing
agents were administered to mice shortly
after clinical onset of CIA. In the first set
of experiments, mice received a single
intraperitoneal injection of neutralizing
anti–IL-18 polyclonal IgG (2 mg). This
treatment resulted in a significant reduc-
tion in disease severity compared with the
control CIA group, which received 2 mg of
normal rabbit IgG (P = 0.0001) (Figure 1, a
and c). In the second set of experiments, a
dose-related study was performed using rhIL-18BP.
Arthritic DBA/1 mice were treated daily, starting at the
first sign of disease, with four different doses of 
rhIL-18BP (0.25 mg/kg, 0.5 mg/kg, 1 mg/kg, and 3
mg/kg, intraperitoneal). Control mice with CIA
received vehicle only (NaCl). As shown in Figure 1, b
and d, the severity of disease was significantly dimin-
ished in the groups treated with rhIL-18BP at 0.5, 1,
and 3 mg/kg (P = 0.01, P = 0.002, and P = 0.03, respec-
tively). Mice receiving the lower dose of rhIL-18BP (0.25
mg/kg) exhibited clinical scores that were not statisti-
cally different from the CIA control group.
Neutralization of IL-18 activity protects joints from destruc-
tion. Both treatments, anti–IL-18 IgG and rhIL-18BP,
resulted in protection of joints from destruction. Fig-
ure 2 shows representative photomicrographs of joints
from naive mice (Figure 2, a and d), arthritic mice (Fig-
ure 2, b and e), and arthritic mice treated therapeuti-
cally with 2 mg/mouse of anti–IL-18 IgG (Figure 2c)
and 3 mg/kg rhIL-18BP (Figure 2f). Joints from the
arthritic control mice showed the expected severe
inflammation of the synovium, with thickening of the
lining layer, infiltration by inflammatory cells, and
presence of pannus overlaying the cartilage. Cartilage
and subchondral bone erosions were also present (Fig-
ure 2, b and e). Cartilage destruction was further
demonstrated by the depletion of matrix proteoglycan,
The Journal of Clinical Investigation | December 2001 | Volume 108 | Number 12 1827
Figure 1
Neutralization of endogenous IL-18 decreases disease severity in CIA mice. (a and b)
Changes in clinical scores over time in DBA/1 mice with type II CIA. CIA mice were
treated intraperitoneally when the first clinical signs of arthritis appeared with: (a)
control IgG (2 mg/mouse) (squares), or anti–mIL-18 IgG (2 mg/mouse) (triangles)
(n = 9, for each dose); and (b) with saline (squares) (n = 16) or rhIL-18BP: 0.25
mg/kg (circles), 0.5 mg/kg (diamonds) (n = 7, for each dose), 1 mg/kg (inverted tri-
angles), and 3 mg/kg (triangles) (n = 16, for each dose). Disease development was
monitored as described in Methods. (c and d) The same results are expressed as the
mean area under the curve (AUC) ± SEM of the clinical scores from the first to the
last day of the experiment after treatment with anti–IL-18 IgG (c) and rhIL-18BP (d).
*P < 0.05, **P < 0.001, ***P < 0.0001, treated versus control groups. 
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as evidenced by safranin O staining (Figure 2b). In con-
trast, joints from CIA mice treated with anti–IL-18 IgG
(2 mg/mouse) and rhIL-18BP (3 mg/kg) showed
markedly less cartilage and fewer bone erosions (Figure
2, c and f). Loss of matrix proteoglycan content in the
cartilage was also much lower, as illustrated by the deep
pink color of the cartilage (Figure 2c), which looked
similar in staining to the normal cartilage (Figure 2a).
However, inflammatory cells, although reduced in the
synovium of the treated mice, were still present, and
many cells were seen in the synovial space (Figure 2, c
and f). A semiquantitative scoring system confirmed
that cartilage erosions were significantly reduced in the
joints of mice that received anti–IL-18 IgG and the
higher doses of 1 mg/kg and 3 mg/kg rhIL-18BP, com-
pared with CIA control mice (P = 0.006, P = 0.05, and 
P = 0.036, respectively) (Figure 3a). No protection was
observed at doses of 0.5 mg/kg or 0.25 mg/kg 
rhIL-18BP (Figure 3a). Histological analysis of three
paws (the first arthritic paw was excluded) confirmed
the reduction in erosion scores resulting from treat-
ment with 1 and 3 mg/kg rhIL-18BP compared with
saline-treated CIA mice (1.92 ± 1.6, n = 30; 2.1 ± 1.3, 
n = 10; and 3.27 ± 2.4, n = 22, respectively).
Additional confirmation of protection against gen-
eral cartilage destruction was obtained by measuring
serum COMP levels. COMP has been validated as a
marker of cartilage turnover during experimental
arthritis, based on a strong correlation between visual
arthritis scores and serum COMP levels (28–30). Sig-
nificant reduction of serum COMP levels was observed
in mice treated either with anti–IL-18 IgG or with 3
mg/kg rhIL-18BP, compared with CIA control mice 
(P = 0.002 and P = 0.02, respectively), whereas serum
COMP levels in mice treated with 1 mg/kg rhIL-18BP
were not reduced significantly (Figure 3, b and c).
Effect of treatment on paw swelling and inflammatory syn-
ovitis. Anti–IL-18 IgG treatment significantly reduced
the inflammatory process as determined by semiquant-
itative scoring of synovial inflammation (P < 0.001;
Table 1) and the development of paw swelling (Figure
4; P < 0.0001). In contrast, rhIL-18BP treatment did not
significantly decrease the synovial inflammation score
of the first arthritic paw at any of the tested doses
(Table 1). Interestingly, when the other paws (first
arthritic paw excluded) were analyzed, treatment with
1 mg/kg and 3 mg/kg rhIL-18BP significantly reduced
the synovial inflammation score (P < 0.05). Macro-
scopic inflammation, measured by the progression of
paw swelling, was reduced significantly by the higher
doses of rhIL-18BP (1 mg/kg and 3 mg/kg; P = 0.04).
However, the treatments with the lower doses of 0.25
mg/kg and 0.5 mg/kg rhIL-18BP had no significant
effect on this parameter.
Reduction of serum IL-6 levels after IL-18 neutralization in
vivo. To gain some insight into the mechanism of action
during IL-18 neutralization, serum levels of IL-6, 
TNF-α, IL-1β, and IFN-γ were measured in the treated
animals at the time of sacrifice. Levels of IL-6 in the sera
of the animals treated with 1 and 3 mg/kg rhIL-18BP
were significantly reduced (P = 0.026 and P = 0.029,
respectively) compared with saline-treated CIA mice (Fig-
ure 5b). Similarly, the levels of bioactive mIL-6 were also
significantly reduced after anti–IL-18 IgG treatment
(P < 0.01), as shown in Figure 5a. Circulating levels of the
other cytokines tested were below the limit of detection.
rhIL-18BP decreases IL-18–induced TNF-α, IL-6, and
IFN-γ secretion by peritoneal macrophages in vitro. The
contribution of macrophage-derived proinflammato-
ry cytokines in CIA is well established (23, 28). There-
fore, to investigate a potential mode of action of 
rhIL-18BP, the ability of rhIL-18BP to control the pro-
duction of proinflammatory cytokines such as 
TNF-α, IL-6, and IFN-γ specifically by macrophages
was investigated. IL-18 directly promoted TNF-α and
IL-6 secretion by peritoneal macrophages; in contrast,
secretion of IFN-γ was induced only by the combina-
tion of IL-18 and IL-12. As hypothesized, TNF-α and
IL-6 levels were reduced to basal values in the presence
of rhIL-18BP (Figure 6, a and b; P = 0.001 and 
P = 0.0007, respectively). Interestingly, the inhibitory
effect of rhIL-18BP was also observed when these
cytokines were induced by the combination of IL-18
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Figure 2
IL-18 neutralization decreases inflammation and cartilage degrada-
tion. At the end of the experiment, the paw that first developed
arthritis was dissected away, fixed, and processed as described in
Methods. (a–c) Safranin O staining. (d–f) Hematoxylin and eosin
staining. (a and d) Normal mouse joint. Joint from control CIA
mouse treated with 2 mg control IgG (b) and with saline (e) show-
ing severe arthritis with cartilage destruction and proteoglycan deple-
tion, with numerous infiltrating cells in the inflamed synovium and
synovial space. (c and f) Joints from mouse treated with 2 mg of
anti–mIL-18 IgG (c) or with 3 mg/kg rhIL-18BP (f). The cartilage
appears well protected despite the presence of inflammatory cells.
Original magnification: ×100 (a–c) and ×200 (d–f).
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and IL-12 (Figure 6, a and b; P = 0.0009 and 
P = 0.0004, respectively). IFN-γ levels were also signif-
icantly decreased in the presence of rhIL-18BP (Figure
6c; P = 0.0001). These data demonstrate that neutral-
ization of IL-18 activity results in decreased produc-
tion of TNF-α, IL-6, and IFN-γ by macrophages, pro-
viding a potential explanation for the protective effect
observed in vivo.
Discussion
The present study was conducted
to assess the anti-rheumatic ther-
apeutic potential of IL-18 neu-
tralization, by investigating the
effect of blocking endogenous IL-
18 in an experimental model of
rheumatoid arthritis. Two dis-
tinct IL-18 neutralizing reagents
were administered therapeutical-
ly to mice with CIA. Our results
clearly demonstrate that blocking
endogenous IL-18 after disease
onset significantly decreases the
clinical symptoms of arthritis,
and, more importantly, that this
therapeutic approach protects joints from further
destruction. The disease-modifying property of the
treatment was demonstrated by a significant decrease
in cartilage erosion scores and reduction of the levels
of COMP in the serum. Neutralization of IL-18 with
the antibody, at the single concentration investigated,
consistently and significantly reduced all parameters
studied, i.e., visual clinical scores, paw swelling, carti-
lage degradation, levels of serum COMP, and IL-6. 
A dose-finding study using rhIL-18BP revealed more
complex pharmacodynamics. The effect of this natu-
rally occurring binding molecule appeared to be
dependent on a threshold concentration. Cartilage
erosions were decreased by the higher doses of 1 and 3
mg/kg, while the lower doses of 0.25 and 0.5 mg/kg
were insufficient to affect this parameter. Similarly,
inflammation, monitored by the progression of paw
swelling during the 7-day treatment, was decreased
only by the two higher doses. The dose effect on the
clinical evolution of disease, monitored by clinical
scores, was somewhat different. The clinical scores rep-
resent the sum of the scores of all four individual
paws, whether diseased or not at initiation of treat-
ment. As the disease develops, randomly and at differ-
ent times in each paw, this parameter reflects not only
the evolution of disease in the affected paw but also
the effect of the treatment on further spreading of dis-
ease to joints that were healthy at the initiation of the
treatment. In this parameter (clinical score), the most
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Figure 3
Neutralization of endogenous IL-18 decreases cartilage destruction
in CIA mice. (a) Erosion scores of arthritic joints after treatment with
2 mg/mouse of control IgG (squares), anti–IL-18 IgG (triangles), and
0 mg/kg (inverted triangles), 0.25 mg/kg (diamonds), 0.5 mg/kg (cir-
cles), 1 mg/kg (open squares), and 3 mg/kg (triangles) of rhIL-18BP,
as indicated. (b and c) Quantification of serum levels of COMP, a
marker of cartilage turnover, after treatment with 2 mg of normal
rabbit IgG (squares) or anti–mIL-18 IgG (triangles) (b), and with
saline (0 rhIL-18BP) (squares) or with 1 mg/kg (triangles) and 3
mg/kg (inverted triangles) rhIL-18BP (c). *P < 0.05, **P = 0.0023,
***P = 0.0006, treated versus control groups.
Table 1
Effect of IL-18 neutralization on synovial inflammation
Treatment Synovial inflammation Synovial inflammation
scores in the first scores in the other 
arthritic paw three paws
(mean ± SEM) (mean ± SEM)
Control IgG 2 mg/mouse 1.85 ± 0.72 n = 18 NSc
Anti–IL-18 IgG 2 mg/mouse 0.80 ± 0.60** n = 18 NSc
rhIL-18BP 0 mg/kg 3.12 ± 0.20 n = 24 5.36 ± 0.62 n = 22
1 mg/kg 2.98 ± 0.40 n = 22 3.61 ± 0.45* n = 30
3 mg/kg 3.04 ± 0.30 n = 16 3.43 ± 0.40* n = 16
Synovial inflammation was scored at the end of the experiments by two independent investigators look-
ing at coded slides. The first clinically affected joint was examined after intraperitoneal treatments with
anti–IL-18 IgG and rhIL-18BP, and scored (maximum = 4). Scoring of the other three paws in the groups
of animals treated with saline, 1 mg/kg rhIL-18BP, and 3 mg/kg rhIL-18BP was also performed (maxi-
mum = 12). Results obtained for each treated group were compared with its control group. *P < 0.05,
**P < 0.01. NSc, not scored.
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efficient doses were 0.5 and 1 mg/kg, whereas 0.25
mg/kg was insufficient and 3 mg/kg was less efficient.
The smaller effect on the clinical score with the dose
of 3 mg/kg was unexpected. 
Several hypotheses can be put forward to explain
these results. One possible explanation is the induc-
tion of a neutralizing antibody response to the bind-
ing protein in the animals receiving the higher con-
centrations of rhIL-18BP. We know that such a
neutralizing polyclonal antiserum can be obtained.
Unfortunately, the high levels of residual rhIL-18BP
present in our treated CIA mice precluded the formal
testing of this hypothesis. Another possibility is that
at this high concentration, rhIL-18BP acts as a depot
for IL-18, preventing clearance, or that it binds to
another related molecule. Unlike soluble cytokine
receptors, IL-18BP is not related to the ligand-binding
chain of the IL-18R. However, it is clear that the
cytokine IL-18 binds to both the soluble IL-18BP and
the cell-bound IL-18R. A recently reported molecule,
IL-1H4 (a human IL-1 homologue) has been shown to
bind to IL-18R (31, 32). IL-1H4 has a high degree of
homology to IL-18. It is therefore possible that 
IL-18BP binds IL-1H4. Because IL-1H4 binds to 
IL-18R, the possibility exists that it would antagonize
IL-18. A similar example has been reported with IL-1
homologues that have high homology to IL-1Ra and
have been shown to be antagonists (33) and to block
IL-1 (weakly). If IL-18BP binds IL-1H4 at high con-
centrations, this may explain the results observed with
the different doses of rhIL-18BP.
Anti–IL-18 IgG and rhIL-18BP treat-
ments had different effects on the syn-
ovial inflammation that was assessed by
scoring cellular infiltration and synovial
hyperplasia. Whereas the antibody treat-
ment decreased synovial inflammation in
the first arthritic paw, treatment with
rhIL-18BP had no effect at any of the
doses tested, although at the higher doses
the treatment was active in reducing car-
tilage degradation. This suggests that
antibody therapy is effective in decreasing
cellular infiltration to joints, synovial
hyperplasia, and release of destructive
enzymes, whereas the binding protein, at
the concentrations tested, is efficient at
decreasing the release of destructive
enzymes but has no effect on cellular infil-
tration and synovial hyperplasia. Howev-
er, our data showing decreased synovial
inflammation in paws other than the first
arthritic paw suggest that neutralization of IL-18
activity acts preventatively to protect from de novo
synovitis during the course of the disease.
Induction of CIA in DBA/1 mice lacking IL-18 showed
reduced incidence and severity of disease, with a signifi-
cant decrease in articular destruction of the first arthrit-
ic paw compared with that of the wild-type control mice
(34). Interestingly, synovial hyperplasia and cellular infil-
tration were not significantly reduced in the absence of
IL-18; this is similar to what we observed after rhIL-18BP
treatment of wild-type DBA/1 CIA mice.
IL-18 has been reported to act directly on synovial
macrophages and articular chondrocytes. In vitro
experiments have demonstrated that IL-18 induces
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Figure 4
Neutralization of IL-18 decreases paw swelling. Progression of swelling was followed
on the first paw that showed clinical signs of disease by measuring paw swelling
using precision calipers. Results are expressed as AUC ± SEM, after treatment with
control IgG (n = 9) or anti–IL-18 IgG (n = 9) and saline (n = 11), or rhIL-18BP at 0.25
mg/kg (n = 7), 0.5 mg/kg (n = 7), 1 mg/kg (n = 12), and 3 mg/kg (n = 12). *P ≤ 0.05,
***P < 0.0001, treated versus control groups.
Figure 5
Neutralization of endogenous IL-18 decreases circulating levels of IL-6.
(a) IL-6 bioactivity present in serum of arthritic mice treated with either
control IgG or anti–IL-18 IgG (n = 9). (b) IL-6 levels measured by ELISA
in the serum of arthritic mice treated with either saline or rhIL-18BP 
(n = 10). *P < 0.05, **P < 0.01, treated versus control groups.
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the release of proinflammatory cytokines by
macrophages, including TNF-α, as well as release of
matrix metalloproteinases and glycosaminoglycan by
articular cartilage, supporting a possible direct con-
tribution of IL-18 in joint destruction (12).
Recently, IL-18 was reported to enhance CIA in
DBA/1 mice injected with CII in incomplete FA (35).
Coadministration of IL-18 changed the low-grade
arthritis seen in DBA/1 mice treated with CII in
incomplete FA to arthritis that was indistinguishable
from that in mice treated with CII in CFA. Treatment
with IL-12 alone or with IL-18 alone promotes CIA,
which is enhanced further by treatment with com-
bined IL-12 and IL-18. IL-18–treated mice produce
more TNF-α and IL-6, through direct effects on
macrophages, but less IFN-γ, than do mice treated
with IL-12. The role of IL-18 together with IL-12 in the
synovium of rheumatoid arthritis may be that of a
potent inducer of TNF-α, IL-6, and IFN-γ production
by locally accumulated macrophages and T cells that
sustain the inflammatory response in the joints.
Indeed, our in vitro experiments demonstrate that 
IL-18 can directly stimulate macrophages to secrete
TNF-α, IL-6, and IFN-γ when IL-18 is combined with
IL-12, and that the induction of these proinflamma-
tory cytokines is inhibited in the presence of 
rhIL-18BP. In vivo treatment with 1 and 3 mg/kg 
rhIL-18BP resulted in high levels of circulating 
rhIL-18BP (23.1 ± 4 and 74.2 ± 6.3 ng/ml, respectively,
n = 5 in each group) measured on the day of sacrifice.
These levels of rhIL-18BP have the potential to com-
pletely neutralize endogenous IL-18 activity, and
therefore account for the protective effect observed.
We observed increased levels of IL-18 and IL-6 dur-
ing the development of CIA, and the levels of IL-6
were significantly reduced by treatment with IL-18
neutralizing agents. Unfortunately, the effect of the
treatment on TNF-α and IFN-γ could not be studied,
because circulating levels of these cytokines were
below the detection limits of the assays, even in the
untreated arthritic animals.
Anti–IL-18 IgG and rhIL-18BP may have distinct
mechanisms of action. IL-18BP bioactivity is not fully
understood; also, anti–IL-18 IgG may have activities in
addition to the neutralization of IL-18, such as modu-
lation of the B cell response that is also known to be
involved in the development of CIA. Collagen-specific
IgG2a antibodies, which are typically produced during
a Th1 response, were unaffected by the rhIL-18BP treat-
ment; in contrast, their titers were significantly
decreased in anti–IL-18 IgG treated mice compared
with mice treated with control IgG (data not shown).
This inhibition of the collagen-specific B cell response,
observed only after anti–IL-18 treatment, may involve
crosslinking of antigen receptors with Fc receptors, and
highlights potential immunomodulation that is spe-
cific to antibody treatment.
Other functions of IL-18 may also be deleterious in
rheumatoid arthritis, further supporting the thera-
peutic strategy of neutralizing this cytokine in this dis-
ease. A recent communication has reported evidence
for IL-18 promoting synovial inflammation through
activation and recruitment of polymorphonuclear neu-
trophils in the synovial compartment (36). Large num-
bers of these cells are present in synovial fluid and at
the cartilage-pannus junction of the synovium, which
is the site of ongoing destruction. Activated neu-
trophils can release proinflammatory cytokines,
including TNF-α and IL-1β, and destructive proteins
such as matrix metalloproteinases.
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Figure 6
rhIL-18BP regulates IL-18–induced TNF-α, IL-6, and IFN-γ produc-
tion by peritoneal macrophages. Macrophages from DBA/1 mice
were enriched by plastic adherence and stimulated with 200 ng/ml
IL-18 (open bars), a combination of IL-12 (100 ng/ml) and IL-18
(200 ng/ml), or cultured with medium alone (black bars), in the
absence or presence of rhIL-18BP (1 µg/ml). Cytokine levels in 24-
hour culture supernatants were measured by ELISA. Data are
expressed as mean ± SEM of triplicate cultures.
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Although the precise mechanisms of action of this
therapeutic approach are not fully understood, the dis-
ease-modifying activity of IL-18 neutralization in an
experimental model of rheumatoid arthritis provides a
rationale to test such a strategy in the clinic.
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